…
ALX Oncology Holdings Inc., a clinical-stage immuno-oncology company, focuses on developing therapies for cancer patients in the United States. The company's lead product candidate is Evorpacept, a CD47 blocking therapeutic biologic development as a combination therapy with other anti-cancer agents, including ASPEN-06, under phase 2 clinical study for treating Gastric/GEJ cancer. It has collaboration agreement for Evorpacept combination programs comprising Jazz Pharmaceuticals plc for zanidatamab, under phase 1b/2 trial for the treatment of breast cancer and other solid tumors; HER2 with an ADC, fam-trastuzumab deruxtecan-nxki, under phase 1 trial for the treatment of patients with breast cancer; ALX2004, under phase 1 clinical trial for treating solid tumors; MD Anderson Cancer Center with rituximab and lenalidomide for the treatment of patients with indolent and aggressive NHL; and Sanofi with isatuximab and dexamethasone, under phase 1/2 trial for the treatment of patients with relapsed or refractory multiple myeloma. It has license agreements with Board of Trustees of Leland Stanford Junior University. The company was incorporated in 2015 and is headquartered in South San Francisco, California.
Source: TradingView
The charts and visual representations are sourced from TradingView through embedded widgets. For any issues with chart display, please visit the TradingView website
A unique technical analysis driven score developed by Kalkine showing momentum in stock prices based on select technical indicators identified.
Alx Oncology Holdings is a clinical-stage biopharmaceutical company developing targeted oncology therapies; public disclosures emphasize a pipeline of investigational cancer candidates. Long-term growth may be driven by clinical trial readouts, regulatory milestones, business development and potential commercialization, which could support value creation and attract investors seeking exposure to oncology innovation.
Note: The summary and risk score provided above is created by AI and should not be construed as a recommendation of Kalkine.
| Breakdown | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Date | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
| Income before tax | -101.69M | -134.85M | -160.81M | -123.42M | -83.48M |
| Net income | -101.69M | -134.85M | -160.81M | -123.48M | -83.46M |
| Selling general administrative | 23.85M | 26.09M | 28.48M | 29.04M | 23.39M |
| Selling and marketing expenses | - | - | 0.84M | - | - |
| Gross profit | - | -0.87M | -0.84M | 0.00M | 0.00M |
| Reconciled depreciation | 0.71M | 0.87M | 0.84M | 0.34M | 0.05M |
| Ebit | - | -133.12M | -159.24M | -127.78M | -83.56M |
| Ebitda | -100.85M | -132.25M | -158.40M | -127.44M | -83.47M |
| Depreciation and amortization | - | 0.87M | 0.84M | 0.34M | 0.08M |
| Non operating income net other | - | - | - | -0.26M | 0.08M |
| Operating income | -100.85M | -142.47M | -170.28M | -127.44M | -83.56M |
| Other operating expenses | 100.85M | 142.47M | 170.28M | 127.44M | 83.56M |
| Interest expense | 1.60M | 1.73M | 1.56M | -4.36M | 0.01M |
| Tax provision | 0.00M | 0.00M | 0.00M | 0.06M | -0.02M |
| Interest income | 3.96M | 9.37M | 10.65M | 4.28M | - |
| Net interest income | 2.36M | 7.64M | 9.08M | 4.28M | -0.01M |
| Income tax expense | - | - | - | 0.06M | -0.02M |
| Total revenue | 0.00M | 0.00M | 0.00M | 0.00M | 0.00M |
| Total operating expenses | 100.85M | 142.47M | 170.28M | 127.44M | 83.56M |
| Cost of revenue | - | 0.87M | 0.84M | 0.00M | 0.00M |
| Total other income expense net | -0.85M | 7.62M | 9.47M | 4.02M | 0.07M |
| Net income from continuing ops | -101.69M | -134.85M | -160.81M | -123.48M | -83.46M |
| Net income applicable to common shares | - | - | - | -123.48M | -83.46M |
| Breakdown | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Date | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
| Total assets | 59.05M | 147.78M | 242.55M | 306.49M | 380.18M |
| Other current assets | 5.64M | 5.70M | 4.92M | 4.76M | 3.35M |
| Total liab | 33.06M | 34.16M | 52.84M | 43.02M | 17.13M |
| Total stockholder equity | 25.98M | 113.62M | 189.71M | -325.47M | -201.99M |
| Deferred long term liab | - | - | - | - | 9.55M |
| Other current liab | 14.42M | 11.66M | 25.84M | 19.21M | 0.26M |
| Common stock | 0.05M | 0.05M | 0.05M | 0.04M | 0.04M |
| Capital stock | 0.05M | 0.05M | 0.05M | 0.04M | 0.04M |
| Retained earnings | -722.82M | -621.12M | -486.27M | -325.47M | -201.99M |
| Other liab | - | - | - | 0.05M | 1.84M |
| Other assets | - | - | - | 9.01M | 12.27M |
| Cash | 16.37M | 17.57M | 22.41M | 282.91M | 363.67M |
| Total current liabilities | 24.55M | 18.50M | 36.00M | 28.32M | 15.29M |
| Current deferred revenue | - | - | - | - | 10.53M |
| Net debt | -11.16M | -0.59M | -5.21M | -272.48M | -362.93M |
| Short term debt | 5.22M | 2.35M | 1.57M | 1.04M | 0.74M |
| Short long term debt | 5.22M | 0.43M | - | - | - |
| Short long term debt total | 5.22M | 16.98M | 17.20M | 10.43M | 0.74M |
| Other stockholder equity | 748.72M | 734.41M | 675.68M | 0.80M | -0.04M |
| Property plant equipment | - | - | - | 3.89M | 0.90M |
| Total current assets | 50.73M | 134.35M | 188.66M | 270.97M | 367.02M |
| Long term investments | 3.49M | 3.52M | 35.41M | 16.70M | - |
| Net tangible assets | - | - | - | 263.46M | 363.05M |
| Short term investments | 28.42M | 110.19M | 160.33M | 217.38M | - |
| Net receivables | 0.30M | 0.89M | 1.00M | - | - |
| Long term debt | 4.53M | 9.47M | 9.64M | 9.39M | - |
| Accounts payable | 4.91M | 4.50M | 8.59M | 8.07M | 3.76M |
| Accumulated other comprehensive income | 0.03M | 0.28M | 0.26M | -0.84M | - |
| Common stock total equity | - | - | - | 0.04M | 0.04M |
| Retained earnings total equity | - | - | - | -325.47M | -201.99M |
| Non currrent assets other | 3.62M | 0.27M | 7.58M | 9.01M | 9.69M |
| Non current assets total | 8.32M | 13.42M | 53.89M | 35.52M | 13.16M |
| Capital lease obligations | - | - | 7.56M | 1.04M | 0.74M |
| Long term debt total | - | - | - | 9.39M | - |
| Breakdown | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Date | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
| Investments | 82.80M | 86.26M | 44.66M | -233.99M | -4.92M |
| Change to liabilities | - | - | - | 10.56M | 3.29M |
| Total cashflows from investing activities | 82.59M | 86.26M | 44.66M | -235.42M | -4.92M |
| Net borrowings | -1.36M | -0.83M | -0.39M | 9.35M | -0.28M |
| Total cash from financing activities | 0.36M | 30.82M | 59.29M | 9.86M | 2.47M |
| Change to operating activities | - | - | - | 5.34M | -7.32M |
| Net income | -101.69M | -134.85M | -160.81M | -123.48M | -83.46M |
| Change in cash | -1.19M | -4.84M | -26.42M | -314.78M | -70.55M |
| Begin period cash flow | 17.63M | 22.47M | 48.89M | 363.67M | 434.22M |
| End period cash flow | 16.44M | 17.63M | 22.47M | 48.89M | 363.67M |
| Total cash from operating activities | -84.14M | -121.91M | -130.36M | -89.22M | -68.10M |
| Issuance of capital stock | 0.00M | 0.00M | 58.89M | 0.00M | 0.00M |
| Depreciation | 0.71M | 0.87M | 0.84M | 0.34M | 0.05M |
| Other cashflows from investing activities | - | - | - | - | -4.26M |
| Dividends paid | - | - | 59.68M | - | - |
| Sale purchase of stock | 0.02M | 0.35M | 0.52M | 0.34M | 0.20M |
| Other cashflows from financing activities | 0.36M | 31.64M | 0.79M | 9.35M | 2.55M |
| Change to netincome | - | - | - | 23.84M | 19.34M |
| Capital expenditures | 0.21M | 0.45M | 1.27M | 1.43M | 4.92M |
| Cash flows other operating | - | - | - | 0.42M | -9.24M |
| Cash and cash equivalents changes | - | - | - | -314.78M | -70.55M |
| Change in working capital | 0.34M | -12.43M | 8.30M | 9.85M | -4.03M |
| Stock based compensation | 12.58M | 27.09M | 26.27M | 23.84M | 13.91M |
| Other non cash items | 3.93M | -2.60M | -4.96M | 0.23M | 5.42M |
| Free cash flow | -84.35M | -122.36M | -131.64M | -90.65M | -73.02M |
Sector: Healthcare Industry: Biotechnology
|
Stock Name
|
Change
(USD) |
Price
(USD) |
Trailing
PE (x) |
Forward
PE (x) |
Price Sales
TTM (x) |
Price to Book Value (x)
|
Enterprise Value
to Revenue (x) |
Enterprise Value
to EBITDA (x) |
|---|---|---|---|---|---|---|---|---|
| ALXO Alx Oncology Holdings |
0.04 4.63% |
1.01 | - | - | 5085.96 | 8.88 | 4287.72 | -2.35 |
| NVO Novo Nordisk A/S |
-0.64 1.64% |
38.79 | 41.58 | 31.15 | 2.13 | 32.99 | 2.11 | 4.70 |
| VRTX Vertex Pharmaceuticals Inc |
-10.99 2.05% |
525.46 | 30.22 | 24.27 | 10.36 | 6.50 | 9.99 | 24.66 |
| REGN Regeneron Pharmaceuticals Inc |
-10.83 1.15% |
934.70 | 29.07 | 20.12 | 7.57 | 3.82 | 6.95 | 19.42 |
| ARGNF argenx SE |
- -% |
965.00 | 45.77 | 31.25 | 13.84 | 7.12 | 11.38 | 36.06 |
ALX Oncology Holdings Inc., a clinical-stage immuno-oncology company, focuses on developing therapies for cancer patients in the United States. The company's lead product candidate is Evorpacept, a CD47 blocking therapeutic biologic development as a combination therapy with other anti-cancer agents, including ASPEN-06, under phase 2 clinical study for treating Gastric/GEJ cancer. It has collaboration agreement for Evorpacept combination programs comprising Jazz Pharmaceuticals plc for zanidatamab, under phase 1b/2 trial for the treatment of breast cancer and other solid tumors; HER2 with an ADC, fam-trastuzumab deruxtecan-nxki, under phase 1 trial for the treatment of patients with breast cancer; ALX2004, under phase 1 clinical trial for treating solid tumors; MD Anderson Cancer Center with rituximab and lenalidomide for the treatment of patients with indolent and aggressive NHL; and Sanofi with isatuximab and dexamethasone, under phase 1/2 trial for the treatment of patients with relapsed or refractory multiple myeloma. It has license agreements with Board of Trustees of Leland Stanford Junior University. The company was incorporated in 2015 and is headquartered in South San Francisco, California.
323 Allerton Avenue, South San Francisco, CA, United States, 94080
650 466 7125
43
| Name | Title | Year Born |
|---|---|---|
| Dr. Corey S. Goodman Ph.D. | Independent Exec. Chairman | 1951 |
| Dr. Jaume Pons Ph.D. | Founder, Pres, CEO & Director | 1967 |
| Mr. Peter S. Garcia M.B.A. | Chief Financial Officer | 1962 |
| Ms. Shelly Pinto | VP of Fin. & Chief Accounting Officer | 1977 |
| Dr. Sophia Randolph M.D., Ph.D. | Chief Medical Officer & Director | 1968 |
| Dr. Michael Chang Ph.D. | VP of Operations | NA |
| Dr. Chris Byrd J.D., Ph.D. | Gen. Counsel | NA |
| Ms. Jeanne Y. Jew | Chief Bus. Officer | 1964 |
| Dr. Athanasios Tsiatis M.D. | Sr. VP of Clinical Devel. | NA |
| Dr. Lin Yeong-Liang M.D., M.S. | Sr. VP of Drug Safety & Pharmacovigilance | NA |
Disclaimer - (*)This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on an ‘as is’ basis, using their API. We cannot guarantee the completeness or validity of the information and data provided on this page, as well as via the API. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general information purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine is not liable for any errors or omissions in the information provided or for any actions taken in reliance on it. You should seek advice from a financial adviser, stockbroker or other professional adviser (including taxation and legal advice) as necessary before acting on this information.